Albion Financial Group UT Sells 140,000 Shares of KORU Medical Systems, Inc. $KRMD

Albion Financial Group UT trimmed its position in shares of KORU Medical Systems, Inc. (NASDAQ:KRMD) by 39.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 216,374 shares of the company’s stock after selling 140,000 shares during the period. Albion Financial Group UT owned approximately 0.47% of KORU Medical Systems worth $829,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in shares of KORU Medical Systems by 189.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after acquiring an additional 158,914 shares during the period. HighTower Advisors LLC raised its position in KORU Medical Systems by 18.4% during the first quarter. HighTower Advisors LLC now owns 51,400 shares of the company’s stock valued at $131,000 after purchasing an additional 8,000 shares in the last quarter. Acuitas Investments LLC acquired a new position in KORU Medical Systems during the second quarter valued at approximately $1,441,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in KORU Medical Systems by 23.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 82,631 shares of the company’s stock worth $296,000 after purchasing an additional 15,714 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of KORU Medical Systems in the 1st quarter valued at $239,000. 58.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Lake Street Capital boosted their price target on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Wednesday, October 8th. Canaccord Genuity Group increased their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Wall Street Zen raised shares of KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, KORU Medical Systems currently has a consensus rating of “Moderate Buy” and an average price target of $5.88.

KORU Medical Systems Stock Down 2.7%

Shares of NASDAQ:KRMD opened at $6.06 on Tuesday. The company has a market capitalization of $280.70 million, a price-to-earnings ratio of -75.75 and a beta of 0.57. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. The business’s 50-day moving average is $5.01 and its 200-day moving average is $4.23. KORU Medical Systems, Inc. has a 1 year low of $1.86 and a 1 year high of $6.61.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.